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Background: Our objective was to conduct a pilot study to determine if transcervical administration of polidocanol foam (PF) with or
without doxycycline or benzalkonium chloride (BZK) would prevent pregnancy in baboons.
Methods: In study phase 1, adult cycling baboons underwent a hysterosalpingogram to evaluate tubal patency prior to transcervical infusion
of 20 mL of 5% PF followed by 1 mL of saline containing 100 mg doxycycline (5%/doxy; n=5), 3% PF plus doxycycline (3%/doxy; n=4),
3% PF with 0.01% BZK (3%/BZK; n=4) or no additional treatment (control; n=9). Immediately following treatment, animals received
intramuscular depot medroxyprogesterone acetate (DMPA, 2 mg/kg) to suppress cyclicity during healing and were then socially housed with
males of proven fertility. The primary outcome was pregnancy within six cycles of resumption of menses (efficacy phase 1). During study
phase 2, PF-treated females from study phase 1 contributed additional cycles (6–8) of exposure (efficacy phase 2), and 5 control females who
had recovered from medical abortion (after study phase 1 pregnancy) were subsequently treated with 5% PF (with DMPA) and exposed to
breeding (efficacy phase 1; n=3 six cycles, n=2 five cycles).
Results: All females resumed normal menstrual cycles and mating activity after DMPA. During efficacy phase 1, 7/9 (78%) control females
became pregnant. In contrast, fewer pregnancies occurred in PF-treated females: 5% PF 0/5 (0%), 5%/doxy 1/5 (20%), 3%/doxy 1/4 (25%)
and 3%/BZK 1/4 (25%). During efficacy phase 2, only one additional pregnancy occurred (3%/BZK).
Conclusions: A single transcervical treatment with 5% PF prevented pregnancy in most baboons. Cotreatment with doxycycline or BZK did
not improve results.
Implications: Transcervical intrauterine administration of PF resulted in a high rate of tubal occlusion with prevention of pregnancy;
refinements are needed to increase the contraceptive rate following a single treatment to near 100%.
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Permanent methods of contraception are appropriate for
women who have completed their desired family size and
who wish never to become pregnant again. Although
vasectomy also provides permanent contraception, around
the world and in the United States, female procedures
predominate [1–3]. Although the limited uptake of vasec-
tomy may reflect poor acceptability by men, many women
prefer female permanent contraception to protect themselves
from undesired future pregnancies. While over 95% of
vasectomized men in the United States report that they are
currently or previously married, over 18% of sterilizedicle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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availability of surgical permanent contraception for women
varies widely in many regions, leading to unmet need for
services [5,6]. The widespread use and preference for female
methods support the development of nonsurgical options.
We have reported that transcervical administration of
polidocanol (hydroxy-polyethoxy-dodecane) foam (PF)
results in tubal occlusion in macaques and baboons [7,8].
In baboons, we observed a dose-dependent histological
effect consistent with complete tubal occlusion (complete
replacement of epithelium with collagen) confined to the
intramural tubal segment in most animals treated with 5% PF
[7]. Hormonal suppression with intramuscular depot
medroxyprogesterone acetate (DMPA) may improve treat-
ment results with PF; complete occlusion was seen in 4/4
females that received 5% PF followed by DMPA but in only
2/3 that received 5% PF without DMPA.
As 5% PF is higher than the concentration currently FDA
approved for vein sclerotherapy (1%), we have performed
pilot investigations of adjunctive agents to improve the
effectiveness of lower concentrations. We previously
reported that the addition of dilute (0.01%) benzalkonium
chloride (BZK) (a common preservative) to polidocanol
improves the stability of the resulting foam [9]. While
unproven, we hypothesize that duration of foam exposure
may be associated with greater tissue effects.
Doxycycline is another venous sclerosing agent [10].
While the effects of coadministration of PF and doxycycline
are unknown, we further hypothesized that combining these
agents could improve the rate of tubal occlusion.
Herein, we conducted a pilot fertility study in baboons to
determine whether a single transcervical treatment with PF
would prevent pregnancy. We evaluated two concentrations
of PF and tested whether the administration of intrauterine
doxycycline as a co-sclerosant or BZK would improve the
contraceptive outcome. We also evaluated the histologic
features induced by these treatments.2. Materials and methods
2.1. Animal care
All study procedures were approved by the Southwest
National Primate Research Center (SNPRC) Institutional
Animal Care and Use Committee. Twenty-two adult female
and two adult male baboons (Papio anubis, Papio anubis/
hamadryus hybrids) of proven fertility were used in this
study. Animal husbandry provided by SNPRC is in accord
with the National Institutes of Health Guidelines for Care
and Use of Laboratory Animals [11]. Menstrual cyclicity
was monitored by evaluation of sex skin tumescence and
confirmed by measurement of serum estradiol and proges-
terone as previously described [7]. Observation of a semen
plug was considered to be evidence of mating. A blood
sample for complete blood count and chemistry panel was
obtained prior to treatment and at the end of study.In an effort to standardize our evaluation of animals, all
females not expected to be in the follicular phase on the day
of evaluation were pretreated with a combined oral
contraceptive (30 mcg ethinyl estradiol/150 mcg levonor-
gestrel) for 15–21 days and then allowed to have a 6–7-day
hormone-free interval prior to treatment to induce a
withdrawal bleed.
2.2. Clinical evaluation of tubal patency
Females underwent a hysterosalpingogram (HSG) proce-
dure to confirm tubal patency as previously described [7].
Briefly, under transabdominal ultrasound guidance, we
passed a small silicone HSG balloon catheter (model
J-CHSG-503000; Cook, Bloomington, IN, USA) through
the cervix into the uterine cavity. A series of digital
radiographs was obtained to evaluate tubal patency (unilat-
eral patent, bilateral patent, bilateral nonpatent) following the
infusion of small aliquots (1–3 mL) of radiopaque contrast
(Isovue®, iopamidol injection; Bracco Diagnostics, Monroe
Township, NJ, USA). At the end of the study, tubal patency
was assessed ex vivo by introducing an HSG catheter
transcervically and then infusing an indigo carmine saline
solution into the uterine cavity under mild pressure
observing for spill of dye from the tubal fimbria.
2.3. Polidocanol foam and adjunctive treatments
Polidocanol 3% and 5% solutions were prepared by
mixing polidocanol stock (Sigma P9641) with sterile
physiologic buffered saline. To prepare polidocanol solution
containing 0.01% BZK, we added BZK (Sigma-Aldrich
234427) to 3% stock polidocanol solution mixing overnight
[9].
We prepared PF using a ratio of 1 mL solution to 4 mL air
to generate 5 mL foam [7]. For all PF treatment groups, a
total of 20 mL of foam was instilled via the HSG catheter
into the uterine cavity over 2–4 min.
Some females received doxycycline (100 mg/mL),
prepared by diluting pharmaceutical-grade doxycycline
powder (Novaplus, Irving, TX, USA) in sterile saline, as a
1-mL bolus via the HSG catheter following the foam
treatment.
All control and PF-treated females received a single dose
of DMPA (2.0 mg/kg, im; Pharma & Upjohn [Pfizer], New
York, NY, USA) immediately following the HSG
examination.
2.4. Contraceptive experiment
The overall design of the contraceptive experiment is
illustrated in Fig. 1. In study phase 1, the initial treatment
groups were 5% PF followed by doxycycline (5%/doxy), 3%
PF plus doxycycline (3%/doxy), 3% PF with 0.01% BZK
(3%/BZK) and untreated controls. We defined the first six
ovulatory cycles of exposure to the male as efficacy phase 1.
Study phase 2 began after completion of this initial efficacy
phase. Nonpregnant PF-treated animals remained in the
Fig. 1. Design of the contraceptive experiment.
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pregnancy (efficacy phase 2). The control group was
disbanded, but a subgroup who had become pregnant and
subsequently recovered from medical abortion underwent a
repeat HSG followed by treatment with 5% PF (no
doxycycline) followed by DMPA. Following resumption
of cycles, these females (5% PF) were reintroduced to the
breeding groups and contributed efficacy phase 1 data.
2.4.1. Establishment of breeding groups
Following recovery, females were socially housed in two
groups that contained a mix of control and PF-treated
animals. After resumption of menstrual cyclicity, an adult
male of proven fertility was introduced to each group.
2.4.2. Verification of ovulatory cycles and mating
At least 3 days per week, females underwent visual
evaluation of sex skin tumescence to assess menstrual cycle
phase and evidence of mating (semen plug) [12].
2.4.3. Evaluation and management of pregnancy
Females that failed to exhibit an expected menses
underwent ultrasound evaluation on approximately cycle
day 35. A diagnosis of pregnancy was confirmed by the
observation of fetal heart activity. In cases where ultrasound
evidence was inconclusive, a serum sample was obtained to
assess for monkey chorionic gonadotropin (mCG) by
radioimmunoassay using antiserum H-26, previously estab-
lished to determine mCG concentrations in blood, urine and
cells, in the Endocrine Technologies Support Core at the
Oregon National Primate Research Center [13]. The standard
curve ranged from 0.005 to 10 ng/tube; the detection limit of
the assay was 0.005–2 ng/tube. Intra- and interassay
variations for this assay were less than 10% and 15%,
respectively.
Pregnant control females underwent medical abortion
with mifepristone (Danco Pharmaceuticals, New York, NY,
USA) 200 mg orally followed by misoprostol (Gavis
Pharmaceuticals, Somerset, NJ, USA) 400–800 mcg vagi-
nally or buccally 24 h later. Animals were singly housedduring the procedure and observed for signs and symptoms
of expulsion. If expulsion did not occur within 24 h, the
misoprostol dose was repeated. Transabdominal ultrasound
was performed after 1 week to monitor treatment success. To
assess possible adverse effects of polidocanol on pregnancy,
PF-treated females underwent induction of labor at term. The
fetus was euthanized to allow for pathologic evaluation.
2.5. Gross and histologic evaluations
Animals underwent necropsy by veterinary pathologists
at the SNPRC Pathology Services Unit according to their
standard protocol for collection of the reproductive tract and
evaluation of other organs. The uterus and cervix, upper
vagina, bilateral tubes and ovaries were extirpated as a single
specimen and prepared for histological evaluation as
previously described [7]. Representative sections through
both corneal areas were further evaluated for histologic
evidence of tubal occlusion (an obliterated lumen in at least a
focal 10× objective field). Immunostaining for cytokeratin,
using routine methods in our laboratory [14], was used to
detect the presence of tubal epithelium when results were
unclear. We also performed immunostaining for collagen 3,
using our previously published methods [15], to better
characterize the treatment effect.
2.6. Data analysis
The primary outcome was the frequency of pregnancy
within treatment groups during efficacy phase 1. Based upon
previous experience of the breeding colony at SNPRC, we
expected that 80% of control females would become
pregnant in 6 months (unpublished data on file, SNPRC).
Although the sample size in the treatment groups is
insufficient for robust statistical analysis, we hypothesized
that zero pregnancies would occur following a successful
treatment.
We used theWilsonmethod (http://epitools.ausvet.com.au)
to calculate 95% confidence intervals (95% CIs) around the
proportion of pregnancies observed in treated and control
females. Secondary outcomes included frequency of
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3%/BZK groups only), histologic evaluation of the intramural
tube and safety.3. Results
3.1. Clinical assessment of tubal patency and treatment
groups
At the initial HSG examination, bilateral tubal patency
was confirmed in 17/22 females. Bilateral patency was
confirmed in all of the females treated with PF; five were
treated with 5% PF/doxy, four received 3% PF/doxy, and
four received 3% PF/BZK. The control group consisted of
nine females that did not receive intrauterine PF; HSG
confirmed bilateral patency in only four. All 22 females
resumed regular menstrual cycles 6–10 weeks after receiving
DMPA, and evidence of mating was recorded in most cycles
(see supplemental material and Supplemental Table 1).
During study phase 2, five females were treated with 5% PF
(no doxycycline); bilateral patency was confirmed in only
four.3.2. Contraceptive effect
During efficacy phase 1 (6 cycles), 7/9 [78% (95% CI,
45%–94%)] control females became pregnant; 1 pregnancy
each occurred in the 5% PF/doxy [1/5, 20% (4%–62%)], 3%
PF/doxy [1/4, 25% (5%–70%)] and 3% PF/BZK [1/4, 25%
(5%–70%)] treatment groups (study phase 1); and no
pregnancies occurred in the 5% PF [0/5, 0% (0%–52%)]
group (study phase 2) (Table 1 and Fig. 2). In the 5% PF
group, three females contributed six cycles of exposure, and
two contributed only five cycles.
During efficacy phase 2, one additional treatment failure
was seen in the 3%/BZK group, bringing the cumulative
failure to 50% (15%–85%). No further pregnancies occurred
in females treated with 5%/doxy or 3%/doxy.Table 1
Number of pregnancies that occurred in baboons during the study
Number (%) pregnant
n Efficacy phase 1 Efficacy phase 2 Cumulative
Study phase 1
Control group 9 7 (78%) – 7/9 (78%)a
5% PF+doxy 5 1 (20%) –
3% PF+doxy 4 1 (25%) –
3% PF+BZK 4 1 (25%) –
Study phase 2
5% PF 5 0 (0%) – 0/5 (0%)a
5% PF+doxy 4 – 0 (0%) 1/5 (20%)
3% PF+doxy 3 – 0 (0%) 1/4 (25%)
3% PF+BZK 3 – 1 (33%) 2/4 (50%)
a Control and 5% PF groups completed efficacy phase 1 only.3.3. Clinical safety
No treatment-related adverse events occurred during the
study. One pregnant control female died of group B
streptococcal sepsis prior to undergoing medication abortion.
All of the pregnancies that occurred in PF-treated animals were
intrauterine and progressed uncomplicated to term. We
performed a feticidal injection prior to induction of labor at
165 days of gestational age; vaginal delivery occurred in three,
and one underwent cesarean section for failed induction. The
fetuses were of normal size and appeared grossly normal (see
Supplemental Table 3) [16].
PF-treated females underwent necropsy either at 4–6
weeks after completion of term pregnancy or after the end of
study phase 2 in females that did not become pregnant (8–17
months after PF treatment). One of the control females
underwent necropsy immediately after death due to sepsis
(see above) and three others 2 months following the
completion of study phase 1. Routine general pathologic
survey and histologic samples (e.g., heart, liver, kidneys and
brain) revealed only minor background findings common in
the baboon population at SNPRC (see Supplemental Table 2
for a summary of pathologic findings). Since PF could
potentially have adverse intraperitoneal effects, we specif-
ically evaluated for the presence of pelvic adhesions.
Significant pelvic adhesions involving the anterior and
posterior cul-de-sac and bilateral fallopian tubes were noted
in only one female (5%/doxy group). Mild adhesions not
involving the tubal fimbriae or ovary were noted in two 5%
PF-treated females (small bowel mesentery to right tube,
anterior cul-de-sac peritoneum to right round ligament) and
in one treated with 3%/BZK (omentum to fundus). The
results of complete blood count and serum chemistry panels
obtained at end of study remained within the normal range
for all assays, with no clinically significant changes from
baseline.
3.4. Clinical and histologic assessment of tubal patency at
end of study
At the end of study, all females treated with PF that did
not become pregnant showed evidence of bilateral tubal
occlusion on the ex vivo dye test, except one animal treated
with 3%/BZK (Table 2).
Females that became pregnant showed normal histologic
features (similar to untreated control animals) in one or both
tubes (Fig. 3). In contrast, histologic evaluation of animals
that failed to conceive generally revealed bilateral oblitera-
tion of the fallopian tube lumen with collagen replacement of
epithelium confined to the intramural tube as we have
previously described [7] (Fig. 3). Exceptions included
unilateral blockade with one normal tube in both of the
females treated with 3% PF/BZK and in one treated with 3%
PF/doxy. One of the females treated with 5% PF also showed
bilateral normal fallopian tubes. This animal had two HSG
exams in study phase 1 that both showed tubal obstruction
prior to control group assignment. She conceived after five
Fig. 2. Time to pregnancy for animals followed during the study. Control group and 5% PF group followed for only six cycles.
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During study phase 2, a third HSG prior to treatment with
5% PF again demonstrated bilateral obstruction. Given the
lack of patency observed during the pre-PF HSG, it is highly
likely that the intramural tube was not adequately treated.
When tubal occlusion developed, the histologic changes
were similar with all treatments. However, treatment with
5% PF (with or without doxycycline) resulted in more
extensive effects than 3% PF (Fig. 3). Furthermore, the two
females treated with 3% PF/BZK that did not become
pregnant showed only unilateral occlusion, with only focal
areas of luminal obstruction and nests of normal epithelium
between these areas.4. Discussion
This is the first study to demonstrate that a single
transcervical administration of polidocanol foam can prevent
pregnancy in primates. We have reported that treatment with
PF results in histologic features of tubal occlusion in rhesusTable 2
Evaluation of tubal patency at end of study in animals that did not become
pregnant
Patency assessment
Treatment Ex vivo dye test Histologic assessment
Occlusion Occlusion
Open Unilateral Bilateral Open Unilateral Bilateral
5% PF/doxy
(n=4)
0 0 4 0 0 4
5% PF (n=5) 0 0 5 1 0 4
3% PF/doxy
(n=3)
0 0 3 0 1 2
3% PF/BZK
(n=2)
0 1 1 0 2 0monkeys [8] and baboons [7]. Herein we show that tubal
occlusion is lasting and thereby provides permanent
contraception. We report that, up to 16 months after PF
treatment, the histologic features of tubal occlusion confined
to the intramural zone persist and that females with bilateral
occlusion fail to conceive.
While encouraging, our results are limited by the small
number of females in each group, which makes comparisons
between adjunctive agents difficult. Although the control
group experienced the expected number of pregnancies and
fewer pregnancies occurred in females treated with PF,
failures did occur with all treatments except 5% PF. Since the
length of exposure to pregnancy was shorter for the 5% PF
group than other treatments, we interpret these results with
caution.
In this study, the presence of histologic tubal occlusion in
the 5% PF treated animals was similar to our previous reports
[7]. We decided to test more than one approach to PF
treatment in order to learn more about potential strategies to
reduce dose and improve efficacy. In our prior study with
baboons, we found that administration of DMPA following
PF treatment improved the rate of complete tubal occlusion
and that 5% PF was superior to 1% [7]. However, only 1%
polidocanol is currently approved for human use in the
United States. Similar to published results in macaques [10],
we found that transcervical administration of doxycycline
results in tubal obstruction in baboons but that more than one
treatment is needed (unpublished results). Therefore, we
hypothesized that intrauterine administration of doxycycline
after PF might provide a second “hit” and allow us to reduce
the concentration of PF. Unfortunately, this combination
failed to increase the rate of success. It is possible that the
administration of doxycycline solution flushed PF from the
intramural tube, reducing the treatment effect in some
animals and allowing healing and normal tubal function. We
also tested whether BZK could improve PF stability and
Fig. 3. Histologic features of the intramural fallopian tube after no treatment (control), 5% polidocanol foam with (5% PF/doxy) and without (5% PF)
doxycycline, and 3% PF with doxycycline (3% PF/doxy) or BZK (3% PF/BZK). Treatment with PF resulted in a loss of tubal epithelium and obliteration of the
lumen. Absence of staining for cytokeratin, an epithelial cell marker, indicates loss of epithelial cells. Staining for collagen 3 demonstrates replacement of
epithelium with connective tissue consistent with a permanent scar. Changes were more prominent in animals treated with 5% PF and less extensive in those
treated with 3% PF/BZK.
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cotreatment also failed to affect the rate of contraception.
While the use of the nonhuman primate model provides a
direct translational link to human medicine, there are
limitations. A major weakness of our study is that the
limitation of animal numbers resulted in very small and
unbalanced treatment groups, and we are missing several
important control groups including 3% PF with no
adjunctive treatment and no additional control cycles of
treatment following successful medical abortion. A further
weakness of our study is that small animal numbers prevent
full quantified evaluation of the histology, and our
impressions are subjective.
Although 5% polidocanol exceeds the 1% strength
currently approved for vein treatments, this higher concen-
tration may be required for adequate sclerosis of the tubal
epithelium and subepithelial tissue to promote collagen
deposition and prevent reepithelialization. To address the
regulatory challenge for approval of this concentration, we
are currently investigating modifications of the delivery
system to reduce the total volume of foam delivered in order
to keep the milligram amount of polidocanol administeredwithin the single-treatment approved range (19.5 mg for
Varithena™).
The risk of ectopic pregnancy is increased following tubal
ligation procedures for permanent contraception [17]. Hieu
et al. [18] performed a case–control study of ectopic
pregnancy in Vietnam and found the risk for quinacrine
sterilization (0.26/1000 woman-years) to be equivalent to
that of surgical sterilization (0.42/1000 woman-years) and
significantly lower than that in women using no method of
contraception. Inadequate treatment with polidocanol foam
could result in tubal damage and increase the risk of ectopic
pregnancy. Although ectopic pregnancy has been reported in
nonhuman primates, it is extremely rare, so assessment of
this risk will await human clinical trials.
Our results support additional investigations of polidoca-
nol foam for permanent contraception. We are currently
evaluating strategies to improve the delivery of PF to
improve efficacy at a lower dose at the Oregon Permanent
Contraception Research Center (https://www.ohsu.edu/
OPERM/).
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.contraception.2016.07.008.
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